Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
Clinical trial NCT07423533 · RECRUITING
Trial details
- NCT number
- NCT07423533
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-30
- Primary completion
- 2027-09-01
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.